Anti-angiogenic therapy for brain tumors targeting neuro-vascular wiring molecules

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04947
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: University of Tsukuba
• Principal Investigator: TAKANO SHINGO 筑波大学, 附属病院, 病院講師 (50292553)
• Co-Investigator(Kenkyū-buntansha): 加藤 幸成 東北大学, 医学系研究科, 教授 (00571811) ; 久保田 義顕 慶應義塾大学, 医学部(信濃町), 教授 (50348687) ; 山下 年晴 筑波大学, 医学医療系, 助教 (50400677) ; 依馬 正次 滋賀医科大学, 動物生命科学研究センター, 教授 (60359578) ; 松田 和郎 獨協医科大学, 医学部, 准教授 (80444446)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 神経膠腫 / 神経血管ワイアリング / 血管新生抑制療法 / lenalidomide / chetomin / 低酸素誘導因子

Outline of Final Research Achievements

In order to make baseline of new anti-angiogenic therapy for glioblastoma, we focused on neurovascularar wiring factors. Among neurovascular wiring factors, we found that slit2 expressed in glioblastoma associated with marked angiogenesis and promoted glioblastoma induced angiogenesis using glioblastoma tissues and cell lines. On therapeutic point, lenalidomide inhibited slit2 mRNA expression and chetomin inhibited cell growth under hypoxia and HIF-1α protein expression. Combined therapy with inhibitors of neurovascular wiring factor, slit2 and HIF-1α promise growth inhibition for glioblastoma.

Free Research Field

脳神経外科